Survival and risk of vascular complications in myelofibrosis—A <scp>population‐based</scp> study from the Swedish <scp>MPN</scp> group-Reference-Cited by-同舟云学术

Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group

Published:2022-06-24 Issue:4 Volume:109 Page:336-342
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Lindgren Marie¹²,Andréasson Björn³,Samuelsson Jan⁴,Pettersson Helna³,Enblom‐Larsson Anneli⁵,Ravn‐Landtblom Anna⁶,Scheding Stefan⁷⁸,Bentham Carolina⁹,Ahlstrand Erik¹⁰^ORCID

Affiliation:

1. Department of Medicine Kalmar County Hospital Kalmar Sweden

2. Faculty of Medicine, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

3. Division of Hematology, Department of Medicine NU Hospital Group Uddevalla Sweden

4. Department of Hematology University Hospital Linköping Linköping Sweden

5. Department of Public Health and Clinical Medicine, Luleå Research Unit Umeå University Umeå Sweden

6. Department of Medicine, Karolinska Institute and Department of Medicine, Division of Hematology Stockholm South Hospital Stockholm Sweden

7. Division of Molecular Hematology, Department of Laboratory Medicine Lund Stem Cell Center, Lund University Lund Sweden

8. Department of Hematology Skåne University Hospital Lund Sweden

9. Department of Medicine Varberg Hospital Varberg Sweden

10. Department of Medicine, Faculty of Medicine and Health Örebro University Örebro Sweden

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13813

Reference27 articles.

1. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

2. Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms

3. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

4. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

5. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24

2. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’;Current Research in Translational Medicine;2024-03

3. Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype;International Journal of Molecular Sciences;2023-10-29